Abstract

Shortly after the original publication of Gentles 1 on the effectiveness of griseofulvin in Trichophyton infections of laboratory animals, numerous investigators have reported on striking clinical results obtained with the oral administration of griseofulvin in treatment of superficial dermatomycoses in man. Williams et al., 2 Riehl, 3 Blank and Roth, 4 and Pardo-Castello 5 were among the first attempting such clinical studies. A main purpose of this paper is to evalu ate the recurrences noted in patients either after completion of a course of oral therapy with griseofulvin or in evidence during the course of treatment . The management of these cases will be discussed. Several patients, moreover, were found to have persistently positive mycological laboratory findings despite apparent clinical cure. This situation we have designated as the healthy carrier state. Method We wish to call attention to the fact that our studies commenced in the winter months and extended into

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.